Positive BEACON data from Jasper Therapeutics (NASDAQ: JSPR) in CSU trial

Rhea-AI Filing Summary

Jasper Therapeutics, Inc. reported that it has released a press release with positive updated clinical data from its BEACON Phase 1b/2a study of subcutaneous briquilimab in adult participants with chronic spontaneous urticaria, along with data from an open-label extension study in chronic spontaneous and chronic inducible urticaria. The company is also hosting a conference call and webinar at 8:00 a.m. Eastern Time on January 8, 2026 to present these updated BEACON and open-label extension results. The press release and the related investor presentation are provided as exhibits to this report.

Insights

Biotech clinical-stage analyst

Jasper shares positive early briquilimab urticaria data and presentation.

Jasper Therapeutics describes positive updated clinical results from its BEACON Phase 1b/2a trial of subcutaneous briquilimab in adults with chronic spontaneous urticaria, plus an open-label extension in chronic spontaneous and chronic inducible urticaria. These are early-stage studies, which typically focus on safety, dosing and initial signs of activity rather than definitive efficacy.

The company is highlighting the data through a dedicated conference call and webinar at 8:00 a.m. Eastern Time on January 8, 2026, supported by a detailed presentation attached as an exhibit. This suggests briquilimab remains an active development priority in urticaria, but the specific magnitude and durability of benefit are not detailed in this excerpt and would need to be taken from the press release and slide deck.

Future interpretation will depend on how the reported outcomes in chronic spontaneous and chronic inducible urticaria compare with current treatment expectations, as described in the attached materials and subsequent company communications.

false 0001788028 0001788028 2026-01-08 2026-01-08 0001788028 JSPR:VotingCommonStockParValue0.0001PerShareMember 2026-01-08 2026-01-08 0001788028 JSPR:RedeemableWarrantsEachTenWarrantsExercisableForOneShareOfVotingCommonStockAtExercisePriceOf115.00Member 2026-01-08 2026-01-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 8, 2026

JASPER THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-39138		84-2984849
(State or Other Jurisdiction Incorporation)		(Commission of  File Number)		(IRS Employer Identification No.)

2200 Bridge Pkwy Suite #102
Redwood City, California 94065

(Address of Principal Executive Offices) (Zip Code)

(650) 549-1400

Registrant’s telephone number, including area code

N/A

(Former Name, or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

(Title of each class)		(Trading Symbol)		(Name of exchange on which registered)
Voting Common Stock, par value $0.0001 per share		JSPR		The Nasdaq Stock Market LLC
Redeemable Warrants, each ten warrants exercisable for one share of Voting Common Stock at an exercise price of $115.00		JSPRW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On January 8, 2026, Jasper Therapeutics, Inc. (the “Company”) issued a press release reporting positive updated clinical data from the Company’s BEACON Phase 1b /2a study of subcutaneous briquilimab in adult participants with chronic spontaneous urticaria (“CSU”), as well as the open-label extension study in CSU and chronic inducible urticaria (“CIndU”), and disclosing that the Company will hold a conference call and webinar at 8:00 am Eastern Time on January 8, 2026 to present the updated data from the BEACON study and the open-label extension study in CSU and CIndU.

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. A copy of the presentation to be used in connection with the conference call and webinar on January 8, 2026 is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated January 8, 2026.
99.2		Presentation – Jasper Therapeutics – BEACON & OLE Data Update, January 8, 2026.
104		Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 8, 2026	JASPER THERAPEUTICS, INC.
	By:	/s/ Herb Cross
	Name:	Herb Cross
	Title:	Chief Financial Officer

2

FAQ

What did Jasper Therapeutics (JSPR) announce in this 8-K?

Jasper Therapeutics announced positive updated clinical data from its BEACON Phase 1b/2a study of subcutaneous briquilimab in adults with chronic spontaneous urticaria and from an open-label extension study in chronic spontaneous and chronic inducible urticaria.

Which Jasper Therapeutics clinical studies are discussed in this update?

The update covers the BEACON Phase 1b/2a study of subcutaneous briquilimab in adult participants with chronic spontaneous urticaria and an open-label extension study in chronic spontaneous urticaria and chronic inducible urticaria.

What is briquilimab in the context of Jasper Therapeutics (JSPR)?

Briquilimab is the drug being studied by Jasper Therapeutics in the BEACON Phase 1b/2a trial and the open-label extension for adult participants with chronic spontaneous urticaria and chronic inducible urticaria.

Is Jasper Therapeutics holding a call to discuss the BEACON data?

Yes. Jasper Therapeutics is holding a conference call and webinar at 8:00 a.m. Eastern Time on January 8, 2026 to present updated data from the BEACON study and the open-label extension study in chronic spontaneous urticaria and chronic inducible urticaria.

Where can investors find more details on Jasper Therapeutics’ BEACON data?

More details are provided in a press release attached as Exhibit 99.1 and a presentation titled “Jasper Therapeutics – BEACON & OLE Data Update, January 8, 2026” attached as Exhibit 99.2.

What exhibits are included with this Jasper Therapeutics 8-K filing?

The exhibits include a press release dated January 8, 2026 (Exhibit 99.1), a BEACON and open-label extension data update presentation dated January 8, 2026 (Exhibit 99.2), and an Inline XBRL cover page data file (Exhibit 104).

On which exchange does Jasper Therapeutics (JSPR) trade and what securities are listed?

Jasper Therapeutics’ voting common stock trades on The Nasdaq Stock Market LLC under the symbol JSPR, and its redeemable warrants trade under the symbol JSPRW.